Price$23.84+0.45 (+1.90%)
01:30 PM07:45 PM
News · 26 weeks71-67%
2025-12-282026-06-21
Mix2690d
- Other10(38%)
- Insider8(31%)
- SEC Filings4(15%)
- Leadership2(8%)
- Earnings1(4%)
- Analyst1(4%)
Latest news
25 items- PRGandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug DiscoveryVancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.VANCOUVER, BC, June 18, 2026 /PRNewswire/ - Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (NASDAQ:ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints on small and flexible antigens remains highly challenging. In
- PRZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (<75% at PS2+) across all dose levels studiedMedian duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months across ovarian and endometrial cancer cohortsPatient recruitment in dose optimization cohorts completed, with favorable tolerability profile and broad therapeutic window supporting continued clinical development VANCOUVER, British Columbia,
- ANALYSTTruist resumed coverage on Zymeworks with a new price targetTruist resumed coverage of Zymeworks with a rating of Buy and set a new price target of $28.00
- INSIDERSEC Form 4 filed by EVP, General Counsel Schneider Paul R4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERNew insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)3 - Zymeworks Inc. (0001937653) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)
- SECZymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockVANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36 per co
- PRZymeworks Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum: Zymeworks' management will participate in one-on-one meetings and a fireside chat on May 20 at 9:00 am Eastern Time (ET) virtually.TD Cowen 7th Annual Oncology Innovation Summit: Zymeworks' management will participate in a fireside chat on May 27 at 4:30 pm ET virtually.2026 Jefferies Global Healthcare Confe
- SECSEC Form 10-Q filed by Zymeworks Inc.10-Q - Zymeworks Inc. (0001937653) (Filer)
- SECZymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial ResultsJazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026China's NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancersPresented on emerging RAS inhibitor antibody-drug co
- PRZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum resistant ovarian cancerMedian duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months in ovarian and endometrial cancer cohortsFavorable tolerability profile and broad therapeutic window support continued clinical development VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a div
- PRZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformSix poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor models New programs include Ly6E, CLDN18.2, and PTK7-targeting ADCs, as well as novel payload and platform innovations New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherape
- PRZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr
- SECSEC Form SCHEDULE 13G filed by Zymeworks Inc.SCHEDULE 13G - Zymeworks Inc. (0001937653) (Subject)
- INSIDERSEC Form 4 filed by Schayowitz Adam4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 4 filed by Platshon Scott4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 3 filed by new insider Platshon Scott3 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schayowitz Adam3 - Zymeworks Inc. (0001937653) (Issuer)
- PRZymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e
- INSIDERSEC Form 4 filed by Stafford Kristin4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stafford Kristin3 - Zymeworks Inc. (0001937653) (Issuer)
- SECSEC Form 8-K filed by Zymeworks Inc.8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Appoints Kristin Stafford as Chief Financial OfficerVANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a
ZYME FAQ
6 questionsWhat does Zymeworks Inc. do?
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic...Where does ZYME stock trade?
Zymeworks Inc. (ZYME) is listed on NYSE.What sector and industry is ZYME in?
Zymeworks Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ZYME?
Zymeworks Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $2800.00 price target on 2026-06-09. Recent price targets range from $1500.00 to $3300.00.What companies are similar to ZYME?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZYME side-by-side with any of them on Quantisnow.How can I track ZYME on Quantisnow?
Quantisnow aggregates Zymeworks Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZYME to receive live email and push alerts on every new disclosure.